Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity.
Hangiu O, Compte M, Dinesen A, Navarro R, Tapia-Galisteo A, Mandrup OA, Erce-Llamazares A, Lázaro-Gorines R, Nehme-Álvarez D, Domínguez-Alonso C, Harwood SL, Alfonso C, Blanco B, Rubio-Pérez L, Jiménez-Reinoso A, Díez-Alonso L, Blanco FJ, Sanz L, Howard KA, Álvarez-Vallina L.
Hangiu O, et al. Among authors: howard ka.
iScience. 2022 Aug 17;25(9):104958. doi: 10.1016/j.isci.2022.104958. eCollection 2022 Sep 16.
iScience. 2022.
PMID: 36072551
Free PMC article.